Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920804 | 0.85 | HRH3 (0.72) | HRH3HRH1KCNH2MAOBMEN1 | |
| SCHEMBL3158474 | 0.84 | HRH3 (0.52) | HRH3HRH1KCNH2MAOBMEN1 | |
| SCHEMBL3158460 | 0.84 | HRH3 (0.52) | HRH3HRH1KCNH2MAOBMEN1 | |
| SCHEMBL3150503 | 0.83 | HRH3 (0.51) | HRH3HRH1KCNH2MAOBS1PR1 | |
| SCHEMBL13437974 | 0.83 | HRH3 (0.56) | GCGRHRH3HRH1KCNH2MAOB | |
| SCHEMBL3150514 | 0.82 | HRH3 (0.49) | HRH3HRH1KCNH2MAOBALDH1A1 | |
| SCHEMBL12376850 | 0.82 | HRH3 (0.73) | GCGRHRH3HRH1KCNH2MAOB | |
| SCHEMBL13438274 | 0.81 | HRH3 (0.56) | GCGRHRH3HRH1KCNH2MAOB | |
| SCHEMBL2284285 | 0.81 | HRH3 (0.60) | HRH3HRH1KCNH2MAOBALDH1A1 | |
| SCHEMBL3150496 | 0.81 | HRH3 (0.48) | HRH3HRH1KCNH2MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989629-B2 | 3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl)-1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as H1 and H3 receptor antagonists for the treatment of inflammatory and/or allergic disorders | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312280-A1 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders | HRH3, HRH1, HRH2 | GCGR 662/4885HRH3 1/4885HRH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.